<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00598611</url>
  </required_header>
  <id_info>
    <org_study_id>P04805-V2.0</org_study_id>
    <secondary_id>EudraCT number: 2006-003686-13</secondary_id>
    <nct_id>NCT00598611</nct_id>
  </id_info>
  <brief_title>Effects of 5 mg vs. 20 mg Desloratadine on Skin Lesions in Patients With Chronic Urticaria (CU)</brief_title>
  <acronym>AUD2OCU</acronym>
  <official_title>An Exploratory Phase III, Randomised, Double-blind, Therapeutic Single Dose-related Effect, Parallel Group Study to Assess and Compare the Effects of 5 mg vs. 20 mg Desloratadine on Skin Lesions in Patients With Chronic Urticaria (CU)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Essex Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare urticaria lesions (size, kinetics) by thermography,&#xD;
      volumetry and digital time lapse photography in CU patients treated with desloratadine 5 mg&#xD;
      or desloratadine 20 mg. Hypothesis: Updosing of desloratadine (20mg) is more efficient in the&#xD;
      treatment of urticarial lesions as compared to standard dosing (5 mg desloratadine).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in size of existing spontaneous urticaria lesions (wheal and flare) as assessed by thermography.</measure>
    <time_frame>5 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in size of existing spontaneous urticaria lesions (wheal and flare) as assessed by volumetry and digital time lapse photography.</measure>
    <time_frame>5 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Chronic Urticaria</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>desloratadine 20 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>desloratadine 20 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>desloratadine</intervention_name>
    <description>singel dose, oral, 20 mg</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>desloratadine</intervention_name>
    <description>single dose, oral, 5 mg</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Outpatients with moderate to severe CU for more than 6 weeks. Urticaria symptoms must&#xD;
             comprise wheal and itch.&#xD;
&#xD;
          2. Patients must exhibit spontaneous urticaria lesions in the randomization visit.&#xD;
&#xD;
          3. History of beneficial effects of antihistaminic treatment.&#xD;
&#xD;
          4. Age between 18 and 60 years.&#xD;
&#xD;
          5. Female patients must be using adequate contraceptive precautions (highly effective&#xD;
             method), or they must be postmenopausal, surgically sterilised, or hysterectomised&#xD;
             (for details please see protocol).&#xD;
&#xD;
          6. Female patients must be using adequate contraceptive precautions (contraceptive pill,&#xD;
             depot, double barrier methods), or they must be postmenopausal, surgically sterilised,&#xD;
             or hysterectomised.&#xD;
&#xD;
          7. Voluntarily signed written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The presence of permanent severe diseases, especially those affecting the immune&#xD;
             system, except CU.&#xD;
&#xD;
          2. The presence of permanent gastrointestinal condition which may influence the oral&#xD;
             therapy (chronic diarrhea diseases, congenital malformations or surgical mutilations&#xD;
             of the gastrointestinal tract).&#xD;
&#xD;
          3. History or presence of epilepsy, significant neurological disorders, cerebrovascular&#xD;
             attacks or ischemia.&#xD;
&#xD;
          4. History or presence of myocardial infarction or cardiac arrhythmia which requires drug&#xD;
             therapy.&#xD;
&#xD;
          5. Evidence of severe renal dysfunction&#xD;
&#xD;
          6. Evidence of significant hepatic disease (liver enzymes twice the upper reference&#xD;
             value).&#xD;
&#xD;
          7. The presence of galactose intolerance, lapp lactase deficiency or glucose galactose&#xD;
             malabsorption.&#xD;
&#xD;
          8. History of adverse reactions including hypersensitivity to DL and Loratadine.&#xD;
&#xD;
          9. Intake of medicaments that could cause QT changes (drugs listed on www.qtdrugs.org).&#xD;
&#xD;
         10. Presence of active cancer which requires chemotherapy or radiation therapy.&#xD;
&#xD;
         11. Presence of acute urticaria / angioedema including laryngeal edema&#xD;
&#xD;
         12. History or presence of alcohol abuse or drug addiction.&#xD;
&#xD;
         13. Participation in any clinical trial within 4 weeks prior to enrolment.&#xD;
&#xD;
         14. Intake of oral corticosteroids or other immunosuppressive therapy within 14 days prior&#xD;
             to the beginning of the study.&#xD;
&#xD;
         15. Use of depot corticosteroids or chronic systemic corticosteroids within 21 days before&#xD;
             beginning of the study.&#xD;
&#xD;
         16. Pregnancy or breast-feeding.&#xD;
&#xD;
         17. Existing or planned placement in an institution after ruling according to ยง 40 passage&#xD;
             1 number 4 AMG (Arzneimittelgesetz).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcus Maurer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Allergie-Centrum-Charite</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allergie-Centrum-Charite</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.urtikaria.net</url>
    <description>Related Info</description>
  </link>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>January 10, 2008</study_first_submitted>
  <study_first_submitted_qc>January 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2008</study_first_posted>
  <last_update_submitted>May 30, 2012</last_update_submitted>
  <last_update_submitted_qc>May 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>K. Weller</investigator_full_name>
    <investigator_title>Dr. Karsten Weller</investigator_title>
  </responsible_party>
  <keyword>urticaria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urticaria</mesh_term>
    <mesh_term>Chronic Urticaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loratadine</mesh_term>
    <mesh_term>Desloratadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

